Literature DB >> 27160545

Unmet need in diabetic nephropathy: failed drugs or trials?

Dick de Zeeuw1, Hiddo J L Heerspink2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27160545     DOI： 10.1016/S2213-8587(16)30045-6

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  13 in total

1.  Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform.

Authors:  Hiddo J L Heerspink; Vlado Perkovic
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-26       Impact factor: 8.237

2.  LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-β-Induced Angiogenesis.

Authors:  Quan Hong; Lu Zhang; Jia Fu; Divya A Verghese; Kinsuk Chauhan; Girish N Nadkarni; Zhengzhe Li; Wenjun Ju; Matthias Kretzler; Guang-Yan Cai; Xiang-Mei Chen; Vivette D D'Agati; Steven G Coca; Detlef Schlondorff; John C He; Kyung Lee
Journal:  J Am Soc Nephrol       Date:  2019-03-11       Impact factor: 10.121

3.  Connectivity Mapping Identifies BI-2536 as a Potential Drug to Treat Diabetic Kidney Disease.

Authors:  Lu Zhang; Zichen Wang; Ruijie Liu; Zhengzhe Li; Jennifer Lin; Megan L Wojciechowicz; Jiyi Huang; Kyung Lee; Avi Ma'ayan; John Cijiang He
Journal:  Diabetes       Date:  2020-10-16       Impact factor: 9.461

4.  Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Authors:  Per-Henrik Groop; Mark E Cooper; Vlado Perkovic; Berthold Hocher; Keizo Kanasaki; Masakazu Haneda; Guntram Schernthaner; Kumar Sharma; Robert C Stanton; Robert Toto; Jessica Cescutti; Maud Gordat; Thomas Meinicke; Audrey Koitka-Weber; Sandra Thiemann; Maximilian von Eynatten
Journal:  Diabetes Obes Metab       Date:  2017-07-31       Impact factor: 6.577

Review 5.  The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

Authors:  Keizo Kanasaki
Journal:  Clin Sci (Lond)       Date:  2018-02-28       Impact factor: 6.124

6.  Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.

Authors:  Hiddo J L Heerspink; Dennis L Andress; George Bakris; John J Brennan; Ricardo Correa-Rotter; Jyotirmoy Dey; Fan Fan Hou; Dalane W Kitzman; Donald Kohan; Hirofumi Makino; John McMurray; Vlado Perkovic; Sheldon Tobe; Melissa Wigderson; Hans-Henrik Parving; Dick de Zeeuw
Journal:  Diabetes Obes Metab       Date:  2018-03-09       Impact factor: 6.577

7.  Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy.

Authors:  Dick de Zeeuw; Hiddo J L Heerspink
Journal:  Nephrol Dial Transplant       Date:  2020-03-01       Impact factor: 5.992

8.  High fractional excretion of glycation adducts is associated with subsequent early decline in renal function in type 1 diabetes.

Authors:  Bruce A Perkins; Naila Rabbani; Andrew Weston; Antonysunil Adaikalakoteswari; Justin A Lee; Leif E Lovblom; Nancy Cardinez; Paul J Thornalley
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

9.  Baseline characteristics and enrichment results from the SONAR trial.

Authors:  Hiddo J L Heerspink; Dennis L Andress; George Bakris; John J Brennan; Ricardo Correa-Rotter; Fan Fan Hou; Dalane W Kitzman; Donald Kohan; Hirofumi Makino; John McMurray; Vlado Perkovic; Sheldon Tobe; Melissa Wigderson; Tingting Yi; Hans-Henrik Parving; Dick de Zeeuw
Journal:  Diabetes Obes Metab       Date:  2018-05-01       Impact factor: 6.577

10.  Mesenchymal stem cells alleviate rat diabetic nephropathy by suppressing CD103+ DCs-mediated CD8+ T cell responses.

Authors:  Fuping Zhang; Chengshi Wang; Xin Wen; Yang Chen; Ruiwen Mao; Danli Cui; Lan Li; Jingping Liu; Younan Chen; Jingqiu Cheng; Yanrong Lu
Journal:  J Cell Mol Med       Date:  2020-04-13       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.